Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2839736 | 0.95 | CTSB (0.43) | CTSSCTSBPDE4B | |
| SCHEMBL2837606 | 0.92 | CTSS (0.40) | CTSSCTSBPDE4APDE4BPDE4C | |
| SCHEMBL2840101 | 0.92 | CTSS (0.42) | CTSSCTSB | |
| SCHEMBL2837887 | 0.91 | CTSS (0.41) | CTSSCTSBPDE4APDE4BPDE4C | |
| SCHEMBL3554588 | 0.89 | CTSB (0.41) | CTSSCTSBPDE4B | |
| SCHEMBL2833502 | 0.86 | CTSS (0.32) | CTSSCTSB | |
| SCHEMBL13501959 | 0.83 | CTSB (0.54) | CTSSCTSB | |
| SCHEMBL2834390 | 0.83 | CTSB (0.54) | CTSSCTSB | |
| SCHEMBL2834380 | 0.83 | CTSB (0.54) | CTSSCTSB | |
| SCHEMBL2839848 | 0.83 | CTSS (0.40) | CTSSCTSBPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| EP-1912981-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | CBR1, HAVCR2, AOC1 | CTSS 624/4885CTSB 1213/4885SGK1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.